MGC Pharmaceuticals (ASX:MXC), a cannabinoid medicines maker, announced it has passed 800 patients with prescriptions of its products in Australia and the United Kingdom (UK).

As quoted in the press release:


Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “This material increase in uptake of prescriptions in such short period of time demonstrates the real patient interest and demand for MGC Pharma’s EUGMP grade phytocannabinoid derived products and cost competitiveness of our medicines in our first 2 markets to be accessed. The increased momentum of new prescribed products in Australia and the UK is yet again a testament to the quality and effectiveness of our phytocannabinoid medicines and growing recognition from, and use by, the medical community and we expect to continue to see this growth in new prescriptions

Further Information

MGC Pharma is pleased to have passed a further key milestone as an emerging bio-pharma company during October, with prescriptions for its phytocannabinoid derived medicines reaching over 800 across Australia and the UK demonstrating its strengthening position in each market. Based on recent prescribed product figures, the Company is on track to exceed 1,000 prescriptions during November 2019. In addition, a number of other patients are being treated with MGC Pharma products globally via participation in ongoing clinical research. The commercialisation of its portfolio of phytocannabinoid derived medicines is in line with its strategy of becoming a world-leading bio-pharma company through international distribution agreements.

Click here to read the full press release.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The following issues have been halted by IIROC:

Company: Avicanna Inc.

Keep reading... Show less

Investment is Expected to Position Cronos Group to Benefit from Rapid Growth in the U.S. Cannabis Market

PharmaCann is Well Positioned in Limited License States Across the Midwest and Northeast

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announced today that it has been issued a Cease Trade Order (“ CTO ”) by the Ontario Securities Commission (the “ OSC ”) as it no longer expects to file the following periodic disclosure documents (collectively, the “ Documents ”) by June 11, 2021, as previously disclosed:

Keep reading... Show less

Adds two accomplished female directors to the Board

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the results of its Annual and Special Meeting of Shareholders held on June 10, 2021 (the “Meeting”). Each of the eight individuals nominated for election as a director of Trulieve at the Meeting were elected, including new nominees, Giannella Alvarez and Jane Morreau .

Keep reading... Show less

The National Football League (NFL) wants to know more about cannabis as a pain reliever, and it’s willing to put up an initial US$1 million for research.

Also this week, a cannabis operator announced plans to buy assets from a languishing producer.

Keep reading... Show less